Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress

Avacta Group plc (AIM: AVCT), a clinical stage life sciences company developing innovative, targeted cancer treatments and powerful diagnostics today announces that it has elected to settle in cash the

AGM Business Update Second Cohort in the AVA6000 Phase 1 Arm 2 Completed, Patient Dosing is Ongoing in Cohort Three Avacta Announces the Assembly of a Scientific Advisory Board to

  Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta’s AVA6000 Phase 1 trial Initiation of FAPI-PET Sub-study in the

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that the abstract of the poster to be presented at the

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and diagnostics, is pleased to announce that, further to its announcement on 28 February 2024, the Company has successfully

Appointment of Christina Coughlin, M.D., Ph.D. as Head of Research and Development

Appointment signals commercial emphasis for Avacta to leverage clinical progress

The data confirm the pre|CISIONTM platform’s ability to transform the safety profile of doxorubicin  through tumour targeting Cohort 7, the final cohort in the three-weekly dose escalation safety study of AVA6000,